A. A. Kolesnikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. A. Kolesnikova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
A. A. Tishchenko
Medical Center for Human Reproduction “Clinic of Professor A. M. Feskov”, Kharkov, Ukraine
1 shared publicationA. M. Feskov
Medical Center for Human Reproduction “Clinic of Professor A. M. Feskov”, Kharkov, Ukraine
1 shared publication- Anastasia Morozyuk
State Institution "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine
1 shared publication - Artem Pochernyaev
SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine; Poltava Scientific Research Forensic Center of the Ministry of Internal Affairs of Ukraine, Poltava, Ukraine
1 shared publication - E. V. Somova
Medical Center for Human Reproduction “Clinic of Professor A. M. Feskov”, Kharkov, Ukraine
1 shared publication I.A. Lurin
1 shared publication
Latest Publications
- Open Access
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 799-806
Adiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 as one of the factors in the pharmacogenetics of type 2 diabetes mellitus
Background. Diabetes mellitus is a syndrome of various etiologies, characterized mainly by chronic hyperglycemia with disorders associated with protein and lipid metabolism. Numerous risk factors for the development of type 2 diabetes have been identified, the most important of which is the pathogenetic contribution of visceral obesity. Adipose tissue is now understood to be an active endocrine organ, secreting various hormones and cytokines that regulate metabolism and inflammation. The ADIPOQ gene located on chromosome 3q27, a region that recent scans of the entire human genome have suggested as a “type 2 diabetes susceptibility locus”, encodes the hormone adiponectin, which is derived from adipose tissue. The purpose of the study is to clarify the role of the adiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 in the mechanisms of pharmacogenetic response in patients with obesity and type 2 diabetes, taking into account the assessment of its impact on the course and effectiveness of therapy. Materials and methods. Sixty-one people were selected for analysis. All patients received oral hypoglycemic drugs: sulfonamides, biguanides or their combination before hospitalization in the clinic. A comparative analysis of a number of biochemical parameters was conducted in the groups that took or did not take metformin as the main sugar-lowering drug, considering the single nucleotide polymorphism of the adiponectin gene. Results. The results indicate that the aforementioned drug has antioxidant properties, a certain hepatoprotective effect (a significant decrease in aspartate and alanine aminotransferase in G allele carriers who received the drug); also, the ability to improve the lipid profile, including in G allele carriers, has been statistically proven, that is, it has the potential to reduce the risk of developing cardiovascular complications, which is the main cause of death in patients. Conclusions. Genetic testing can be used to divide patients with type 2 diabetes and obesity into specific clusters and/or endophenotypes. Advances in the field of pharmacogenomics will allow clinicians to select personalized drug therapy regimens in order to increase its effectiveness and reduce the risk of developing adverse events.
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 799-806
Open AccessAdiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 as one of the factors in the pharmacogenetics of type 2 diabetes mellitus
Background. Diabetes mellitus is a syndrome of various etiologies, characterized mainly by chronic hyperglycemia with disorders associated with protein and lipid metabolism. Numerous risk factors for the development of type 2 diabetes have been identified, the most important of which is the pathogenetic contribution of visceral obesity. Adipose tissue is now understood to be an active endocrine organ, secreting various hormones and cytokines that regulate metabolism and inflammation. The ADIPOQ gene located on chromosome 3q27, a region that recent scans of the entire human genome have suggested as a “type 2 diabetes susceptibility locus”, encodes the hormone adiponectin, which is derived from adipose tissue. The purpose of the study is to clarify the role of the adiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 in the mechanisms of pharmacogenetic response in patients with obesity and type 2 diabetes, taking into account the assessment of its impact on the course and effectiveness of therapy. Materials and methods. Sixty-one people were selected for analysis. All patients received oral hypoglycemic drugs: sulfonamides, biguanides or their combination before hospitalization in the clinic. A comparative analysis of a number of biochemical parameters was conducted in the groups that took or did not take metformin as the main sugar-lowering drug, considering the single nucleotide polymorphism of the adiponectin gene. Results. The results indicate that the aforementioned drug has antioxidant properties, a certain hepatoprotective effect (a significant decrease in aspartate and alanine aminotransferase in G allele carriers who received the drug); also, the ability to improve the lipid profile, including in G allele carriers, has been statistically proven, that is, it has the potential to reduce the risk of developing cardiovascular complications, which is the main cause of death in patients. Conclusions. Genetic testing can be used to divide patients with type 2 diabetes and obesity into specific clusters and/or endophenotypes. Advances in the field of pharmacogenomics will allow clinicians to select personalized drug therapy regimens in order to increase its effectiveness and reduce the risk of developing adverse events.
- 9 September 2023
- Published by Springer Nature in Measurement Techniques
- Vol. 66 (5) , 1-8
Measurements of Electrical Characteristics of Mammalian Oocytes
- 9 September 2023
- Published by Springer Nature in Measurement Techniques
- Vol. 66 (5) , 1-8
Measurements of Electrical Characteristics of Mammalian Oocytes